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RhoG is a member of the Rho family of small GTPases
and shares high sequence identity with Rac1 and Cdc42.
Previous studies suggested that RhoG mediates its ef-
fects through activation of Rac1 and Cdc42. To further
understand the mechanism of RhoG signaling, we stud-
ied its potential activation pathways, downstream sig-
naling properties, and functional relationship to Rac1
and Cdc42 in vivo. First, we determined that RhoG was
regulated by guanine nucleotide exchange factors that
also activate Rac and/or Cdc42. Vav2 (which activates
RhoA, Rac1, and Cdc42) and to a lesser degree Dbs
(which activates RhoA and Cdc42) activated RhoG in
vitro. Thus, RhoG may be activated concurrently with
Rac1 and Cdc42. Second, some effectors of Rac/Cdc42
(IQGAP2, MLK-3, PLD1), but not others (e.g. PAKs,
POSH, WASP, Par-6, IRSp53), interacted with RhoG in a
GTP-dependent manner. Third, consistent with this dif-
ferential interaction with effectors, activated RhoG
stimulated some (JNK and Akt) but not other (SRF and
NF-B) downstream signaling targets of activated Rac1
and Cdc42. Finally, transient transduction of a tat-
tagged Rac1(17N) dominant-negative fusion protein in-
hibited the induction of lamellipodia by the Rac-specific
activator, Tiam1, but not by activated RhoG. Together,
these data argue that RhoG function is mediated by
signals independent of Rac1 and Cdc42 activation and
instead by direct utilization of a subset of common
effectors.
The Rho family of small GTPases constitutes a major branch
of the Ras superfamily of proteins, and like the other Ras-like
GTPases, they function as GDP/GTP-regulated molecular
switches where the GTP bound form is active and the GDP
bound is inactive (1, 2). Proteins in the Rho family are activated
by guanine nucleotide exchange factors (GEFs)1 and inacti-
vated by GTPase-activating proteins (GAPs). GEFs stimulate
the exchange of GDP for GTP on the GTPase. Rho GEFs are
also referred to as Dbl family proteins, and all members possess
a tandem Dbl homology (DH) catalytic domain and a pleckstrin
homology (PH) regulatory domain structure (3, 4). GAPs inac-
tivate Rho proteins via stimulation of their intrinsic GTPase
activity (5). Rho family proteins have an additional group of
negative regulatory proteins, guanine nucleotide dissociation
inhibitors, that both inhibit nucleotide exchange and regulate
Rho protein association with membranes (6).
Currently, at least 18 mammalian Rho family GTPases have
been identified, and Cdc42, Rac1, and RhoA have been the most
extensively studied and characterized. Perhaps the best char-
acterized function of Rho proteins is their ability to regulate the
actin cytoskeleton and thereby regulate cell morphology, adhe-
sion, and migration (7, 8). Cdc42 induces actin polymerization
and the formation of filopodia in conjunction with its regulation
of cell polarity (9–11). Rac1 typically controls cell protrusion
through actin polymerization, formation of lamellipodia, and
membrane ruffles (12). The characteristic property of RhoA is
its stimulation of myosin-based contractility, which in turn
controls focal adhesion and stress-fiber formation as well as
cellular adhesion and motility (13, 14). In addition, Rho GTP-
ases also regulate gene transcription and cell proliferation and
are required for the transforming activity of Ras and other
oncoproteins (15, 16).
RhoG is most similar to Rac1 and Cdc42 in sequence identity
(72 and 62%, respectively) and function. Earlier studies sug-
gested that RhoG stimulates pathways distinct from those
activated by Cdc42 and Rac1. This conclusion was based on the
finding that co-expression of activated RhoG together with
activated Rac1 and Cdc42 caused a 4-fold enhancement of the
transforming activity that was seen with only Rac1 and Cdc42
(17). However, more recent studies support a model in which
RhoG mediates similar functions as Rac and Cdc42 by causing
the downstream activation of Rac and Cdc42. For example,
activated RhoG caused actin cytoskeletal changes in NIH 3T3
cells consistent with simultaneous activation of Rac and Cdc42
(18). Additionally, it was demonstrated that dominant-negative
mutants of Cdc42 and Rac1 could block RhoG-induced neurite
outgrowth in PC12 cells (19). Finally, transient expression of
activated RhoG increased the activation of endogenous Cdc42
and Rac1 (19), suggesting that RhoG signals through Cdc42
and Rac1. The manner in which RhoG causes the activation of
Cdc42 and Rac1 was not determined
Presently, little is known regarding the upstream signals
that cause RhoG activation and the effectors of RhoG function.
Extracellular stimuli cause activation of Rho GTPase primarily
through the activation of Dbl-family GEFs. Several Dbl family
members (Vav2, Vav3, and Trio) have been found to activate
RhoG in vitro (20–22). Because these GEFs also activate Rac,
Rac and RhoG may be activated concurrently rather than se-
quentially. Downstream, little is known about RhoG effector
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binding. In yeast two-hybrid binding analyses, it was deter-
mined that RhoG did not interact with Pak1, POR-1, or WASP
(18), three binding partners of Rac and/or Cdc42, arguing that
RhoG cannot mediate Rac/Cdc42-associated events via the uti-
lization of effectors shared with Rac or Cdc42.
To further evaluate the relationship between RhoG and
Cdc42/Rac signaling, we tested the ability of RhoG to bind and
become activated by Rac or Cdc42 GEFs, to bind to effectors of
Rac and Cdc42, to activate downstream signaling pathways
stimulated by Rac and Cdc42, and to determine whether RhoG
specifically activates Cdc42 and Rac1. Our results strongly
indicate that in our cell system, RhoG mediates its effects
independent of an activation of Rac1 and Cdc42.
MATERIALS AND METHODS
DNA Constructs—We isolated cDNA sequences encoding RhoG by
polymerase chain reaction (PCR)-mediated DNA amplification from two
different human cDNA libraries. Both cDNA sequences were identical
to those described previously for wild-type RhoG (Genbank accession
no. XM006153). We then utilized this sequence to generate mutant
sequences encoding dominant-negative (G15A and T17N) and domi-
nant-activated (Q61L) by using the QuikChange mutagenesis kit
(Stratagene). Wild-type and mutated RhoG cDNAs were subsequently
subcloned into the pGEX 4T-1 (Amersham Biosciences) bacterial, or
pEGFP-C3 (Clontech), and pCDNA3 (Invitrogen) (with an addition of
an NH2-terminal hemaglutinin (HA) tag) mammalian expression vec-
tors. Similarly, bacterial expression vectors for wild-type and mutant
(G15/17A and Q61/63L) human Cdc42, Rac1, and RhoA were made by
subcloning cDNA sequences encoding these proteins into pGEX 4T-1 for
expression of glutathione S-transferase (GST)-tagged fusion proteins.
cDNA sequences encoding green fluorescent protein (GFP)-tagged acti-
vated (Q61L) and dominant-negative (T17N) Rac1 were made by mu-
tagenesis of human wild-type Rac1 using the QuikChange mutagenesis
kit (Stratagene) and were then subcloned into pEGFP-C3. cDNA se-
quences encoding a GFP-tagged fragment of the tandem DH-PH do-
mains of Tiam1 were excised from the Tiam1 DH-PH fragment from the
pCGN-Tiam1 DH-PH plasmid vector (23) and subcloned into
pEGFP-C1 (Clontech). cDNA sequences encoding a GFP-tagged frag-
ment of the RhoA-GTP binding domain (RBD) of rhotekin, a RhoA-
specific effector, was made by PCR-mediated DNA amplification from a
pGEX-rhotekin RBD plasmid construct (24) and subcloned into pEGFP-
C1. cDNA sequences encoding an HA epitope-tagged fragment of the
Cdc42-specific, partial CRIB domain-containing effector IRSp53 SH3
was made by PCR-mediated DNA amplification of the cDNA sequence
encoding amino acids 1–364 from a human cDNA library and then
subcloned into the pCGN-hygro mammalian expression vector. Mam-
malian expression vectors for expression of Vav1, Vav2, Dbl, Dbs, Ect2,
Lfc, LARG, MLK3, and Rac1(17N) have been described previously by
our laboratories (25–33). The following DNA constructs were kindly
provided by others: pEGFP ITSN DH-PH (Dr. Wendy Morse-Pruitt,
University of North Carolina, Chapel Hill, NC), pCMY-122 (Myc-tagged
RhoGIP122) (Dr. Anne Blangy, Centre de Recherches en Biochimie
Macromoleculaire, France), pJ3 IQGAP2 (Dr André Bernards, Har-
vard Medical School, Cambridge, MA), pCGN PLD1 (Dr. Andrew J.
Morris, University of North Carolina, Chapel Hill, NC), pCMV6 M
Pak1, pCDNA His3(T7) Pak5, pCMV6 M Pak6 (Dr. Jonathan Chernoff,
Fox Chase Cancer Center, PA), pYDF30 WASP GBD (Dr. Mark Sy-
mons, The Picower Institute for Medical Research, NY), pRK5 POSH
RBD and pBabe T7 PAR6 (Dr. Antoine Karnoub, University of North
Carolina, Chapel Hill, NC), pCMV-Myc p50RhoGAP (Dr. Jian Zhong,
University of North Carolina, Chapel Hill, NC), pTat-HA Rac1(17N)
(Dr. Steven F. Dowdy, Washington University, St. Louis, MO), pEGFP
Cdc42(61L) (Dr. Mark Philips, New York University, NY), and Myc
epitope-tagged Tiam1 C1199 (a constitutively activated truncated var-
iant), pAC 90 M-1 (Gideon Bollag, Onyx Pharmaceuticals).
Cell Culture, Transfections, and Protein Transduction—NIH 3T3
cells were grown in Dulbecco’s modified Eagles medium (Sigma) sup-
plemented with 10% bovine calf serum (Sigma) and penicillin/strepto-
mycin/fungizone (Invitrogen). DNA transfections were done by using
LipofectAMINE Plus (Invitrogen) by the protocol recommended by the
manufacturer. Microinjections were done by plating cells on 35-mm
culture dishes with 1.2 mm glass bottoms (MatTek Corp.) 24 h before
injection. On the day of injection, normal growth medium was replaced
by microinjection medium (50% normal growth medium and 50% of
Hank’s balanced saline solution buffered with 10 mM HEPES, pH 7.2),
and the cultures were placed under phase contrast at 400 on a Nikon
Eclipse TE300 inverted fluorescent microscope, and expression vector
plasmids diluted to 25 ng/l in double distilled H2O were injected.
Nuclear injections were performed using an Eppendorf Microinjection
System (InjectMan 5179 and Femtojet 5246, Eppendorf) at a pressure of
20 hPa. To control the injection process and identify microinjected cells,
rhodamine-labeled dextran (Sigma) was mixed with the DNA at final a
concentration of 10 mg/ml. Approximately 25 cells were injected for
each condition. After microinjection, cells were changed back to normal
growth medium and incubated at 37 °C in a 10% CO2 incubator for 3 h
before fixing and immunofluorescent staining. For transduction of tat-
tagged bacterial fusion proteins, cells were plated on glass coverslips on
day 0, LipofectAMINE-mediated transfection with pEGFP RhoG(61L),
Rac1(61L), or Tiam1 DH-PH day 1, and tat-Rac1(17N) was added at a
concentration of 50 g/ml in serum-free medium at day 2 for 3 h before
cells were fixed and stained. Bacterially expressed tat-tagged protein
was purified and delivered to cells (50 g/ml) as described previously
(34). For LipofectAMINE-mediated transduction of GST or GST-Pak1
PBD, the cells were plated on coverslips in 24-well plates and trans-
fected as described above with expression plasmid DNAs encoding the
indicated proteins. The day after the transfection, 5 g of GST or
GST-Pak1 PBD protein was mixed with 5 l of LipofectAMINE and
then added to each well in serum-free medium. Two h after the addition
of the protein-LipofectAMINE mix, the cells were fixed and stained.
Immunofluorescent labeling for the transduced protein showed that at
least 90% of the cells had taken up the protein.
GEF and Effector Binding to Rho Proteins—In vitro protein interac-
tion analyses between cellularly expressed GEFs or effectors to recom-
binant Rho proteins was performed as described previously (31).
Briefly, epitope-tagged GEFs or effectors were transiently overex-
pressed in NIH 3T3 cells by LipofectAMINE Plus transfection. Twenty-
four h post-transfection, cells were lysed and GST or GST-tagged ver-
sions of Rho proteins were bound to glutathione Sepharose beads
(Amersham Biosciences) were added to the lysates and rotated for 30
min. The beads were washed three times with lysis buffer, and the
bound material was subjected to SDS-PAGE and Western blot analyses
with antibodies that recognize the epitope tag associated with each
expressed protein (anti-Myc 9E10, Sigma; anti-HA HA11, Covance;
anti-GFP, Clontech; anti-T7, Novagen). For GEF binding assays, bac-
terially expressed protein for nucleotide-free G15A (G17A in RhoA)
mutants of the Rho proteins were used. For effector binding assays, the
GTPase-deficient, constitutively GTP-bound Q61L (Q63L in RhoA) mu-
tants were used.
In Vitro Exchange Assays—Fluorescence spectroscopic analysis of
N-methylanthraniloyl-GTP incorporation into GDP-preloaded GST-
RhoG was carried out using a FLUOstar fluorescence microplate reader
(BMG Lab Technologies) at 25 °C using procedures similar to those
described previously (35). Exchange reaction assay mixtures containing
20 mM Tris, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol, 50
mg/ml bovine serum albumin, 1% glycerol, 500 nM N-methylanthra-
niloyl-GTP (Biomol), and 2 M GTPase were prepared and allowed to
equilibrate by shaking. At the indicated time, bacterially expressed
Vav2 DH-PH-CRD (100 nM), Dbs DH-PH (150 nM), Tiam-1 DH-PH (150
nM), or Dbl DH-PH (150 nM) was added and the relative N-methylan-
thraniloyl fluorescence (excitation  360 nm, emission  455 nm) was
monitored. Experiments were performed in triplicate. The DH-PH pro-
teins were kind gifts from Drs. Michelle Booden (Vav2) and John
Sondek (Dbs, Dbl, and Tiam1) (University of North Carolina, Chapel
Hill, NC).
Immunofluorescence—NIH 3T3 cells were transiently transfected
with expression constructs encoding the indicated protein 24 h before
they were fixed with paraformaldehyde, permeabilized with Triton
X-100, stained with Texas Red-labeled phalloidin (Molecular Probes),
and mounted on slides. Fluorescence microscopy was performed with a
Zeiss Axioscope equipped with a MicroMAX 5-MHz cooled charge-cou-
pled device camera (Princeton Instruments) and analyzed using Meta-
morph software (Universal Imaging Corp.).
Cdc42/Rac1/RhoA Activity Assays—Assays for the nucleotide bound
status of Cdc42, Rac1, and RhoA was performed as described previously
(36, 37) by LipofectAMINE transfection of NIH 3T3 cells 24 h before
they were lysed and subjected to pull-down assays with either GST-
Pak1 PBD (for GTP-bound Cdc42 and Rac1) or GST-rhotekin RBD (for
GTP-bound RhoA) bound to glutathione Sepharose beads, run on SDS-
PAGE, gels and the subject to Western blot analysis with antibodies
specific for Cdc42, Rac1, or RhoA (Transduction Laboratories). To con-
trol for equal cellular protein being used in each sample, total cell
lysates were also run on gels and subjected to Western blot analysis for
the Rho protein tested.
Downstream Signaling Pathway Activation Assays—Assays for acti-
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vation of JNK, Akt, and Pak1 were done by transiently transfecting
NIH 3T3 cells with the empty vector alone, or vectors encoding acti-
vated Rho proteins or GEFs, followed by 20 h of serum starvation in
medium supplemented with 0.5% serum prior to lysis in SDS-PAGE
sample buffer, separation by SDS-PAGE, and immunoblot analysis for
phosphorylated and activated JNK or Akt with phospho-specific anti-
bodies (Cell Signaling catalog number 9271 and 9255, respectively) and
total JNK and Akt (Cell Signaling). For Pak1 activation assays, an
expression vector for a Myc epitope-tagged Pak1 was co-transfected
with the constructs to be tested, to increase the sensitivity of the assay.
The remainder of the assay was done as described for JNK and Akt but
with a phospho-specific Pak1 antibody (a kind gift from Dr. Jonathan
Chernoff, Fox Chase Cancer Center, Philadelphia, PA) and a Myc
epitope antibody (9E10, Sigma). Activation of serum response factor
(SRF) and NF-B was determined by co-transfecting the expression
construct to be tested with reporter plasmids in which the luciferase
gene is under the control of an SRF- or an NF-B-responsive minimal
promoter sequence 24 h before lysis of the cells and luciferase activity
was analyzed using enhanced chemiluminescence reagents and a Mono-
light 2010 luminometer (Analytical Luminescence) as described previ-
ously (38).
RESULTS
RhoG Can Be Activated by GEFs That Also Activate RhoA,
Rac1, and Cdc42—Extracellular stimuli cause activation of
Rho GTPases most commonly through activation of Dbl-family
proteins. Thus, to better understand the stimuli by which RhoG
could be activated in cells, we evaluated the ability of a variety
of Dbl family proteins to activate RhoG. For these analyses, we
determined the ability of the isolated DH/PH domains of vari-
ous Dbl family proteins to bind nucleotide-free RhoG or to
stimulate the exchange of guanine nucleotide on wild-type
RhoG in vitro (Fig. 1). Vav1 and Vav2 are two highly related
GEFs for Rac and Cdc42 (26, 32), and both bound strongly to
RhoG and a DH-PH fragment of Vav2 efficiently stimulated
guanine nucleotide exchange in vitro. The related RhoA and
Cdc42 GEFs, Dbl and Dbs (28, 39), both bound weakly to
nucleotide-free RhoG, but only Dbs stimulated guanine nucle-
otide exchange activity on RhoG in vitro. Ect2 has been de-
scribed as a RhoA and Rac-specific GEF (40) and it also bound
weakly to nucleotide-free RhoG. In contrast, the Cdc42-specific
GEF intersectin-L (41, 42) did not bind RhoG and the Rac-
specific GEF Tiam1 (43, 44) did not bind or stimulate the
exchange of nucleotide on RhoG. Finally, the RhoA-specific
exchange factors LARG (31) and Lfc (45) did not bind to RhoG.
In the cases in which binding and exchange of nucleotide were
both tested, we observed a direct correlation between the two
assays for all the Rho proteins described. However, one excep-
tion involved Dbl, which did bind nucleotide-free RhoG in our
assays, although surprisingly did not stimulate the exchange of
nucleotide on wild-type RhoG. From these data, we concluded
that RhoG can be activated by a variety of GEFs known to
activate Rac and/or Cdc42.
RhoG Interacts with Some, but Not All, Rac And Cdc42
Effectors—RhoG has been found previously not to interact with
the Rac1 and/or Cdc42-specific effectors Pak1, WASP, and
POR-1 when analyzed by two-hybrid binding assays (18). To
further evaluate the ability of RhoG to interact with effectors of
RhoA, Rac, and/or Cdc42, we performed pull-down analyses
using bacterially expressed GST-tagged fusion proteins of ac-
tivated mutants of Cdc42, Rac1, RhoG, and RhoA with lysates
of cells in which Rho protein effectors had been transiently
expressed (Fig. 2). Similar to previous observations, we found
that RhoG did not bind Pak1 and WASP. In addition, it did not
bind to Pak5, Pak6, PAR6, IRSp53, or POSH. Activated RhoG
did, on the other hand, bind to the previously reported RhoG-
binding fragment RhoGIP122, as well as the Rac/Cdc42-spe-
cific effectors MLK3, PLD1, and IQGAP2 (Fig. 2). All four of
these interactions were shown to depend on GTP loading of the
GTPase, because the binding to wild-type (GDP-loaded) RhoG
was strongly diminished. These new potential RhoG effectors
include both CRIB-domain containing (MLK3) and non-CRIB
(IQGAP2 and PLD1) effectors. Furthermore, we could not de-
tect RhoG binding to the RhoA effector rhotekin or the two
RhoGAPs, p50 and p190 (data not shown). These data indicate
that RhoG signals, in part, through some of the same down-
stream effectors as Cdc42 and Rac1.
Activated RhoG and Rac1 Cause Similar Changes in Cell
Morphology and Actin Organization—When transiently ex-
pressed as a GFP-tagged (Fig. 3) or an HA epitope-tagged (data
not shown) protein in NIH 3T3 cells, an activated Q61L mutant
(RhoG(61L)) (Fig. 3, C and D) gave a change in cell shape and
actin organization similar to what was seen in cells expressing
Rac1(61L) (Fig. 3, E and F). However, with Rac1(61L), lamel-
lipodia formed in all directions around the periphery of the cell,
whereas with RhoG(61L), lamellipodia often developed at sev-
eral regions but were absent from one end of the cell, resulting
in a more polarized appearance. In contrast, expression of
Cdc42(61L) caused a limited formation of filopodia (Fig. 3, G
and H), and when co-expressed with Rac1(61L) the two to-
gether were unable to reconstitute the polarized morphology of
RhoG(61L)-expressing cells (Fig. 3, I and J). Interestingly, the
RhoG(61L)-induced morphology is similar to what was seen
when an activated mutant of Vav2, an activator of Cdc42, Rac1,
and RhoG, was expressed in these cells (Fig. 3, K and L),
FIG. 1. Dbl family protein interaction with and activation of
RhoG. A, RhoG association with Dbl family proteins in vitro. The
indicated Dbl-family proteins were expressed transiently in NIH 3T3
cells as HA- or GFP-epitope-tagged fusion proteins. The cells were then
lysed and used to evaluate the ability of bacterially expressed domi-
nant-negative Rho GTPases to form stable complexes. The association
of each Dbl family protein was assessed by SDS-PAGE and Western blot
analysis using anti-HA or -GFP monoclonal antibody. B, Dbl family
protein stimulation of guanine nucleotide exchange on RhoG. Fluores-
cence spectroscopic analysis of N-methylanthraniloyl-GTP incorpora-
tion into GDP-preloaded recombinant GST-RhoG by bacterially ex-
pressed DH/PH domain-containing fragments of Vav2, Dbl, Dbs, and
Tiam1 was done as described under “Materials and Methods.” Inserts
represent nucleotide exchange activity of Tiam1 (Rac1) and Dbl (Cdc42)
used in these experiments. Data shown are representative of three
independent experiments, with each performed in duplicate.
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indicating that Vav2 might mediate its morphological effects
partly through activation of RhoG. These results suggest that
RhoG, in part, might regulate cell protrusions by unique mech-
anisms that do not involve the activation of Rac1 and Cdc42.
Overexpression of Activated RhoG, As Well As Activated Rac1
and Cdc42, Leads to Activation of Endogenous Rac1 and
Cdc42—Pull-down analyses showed previously that transient
overexpression of activated RhoG in PC12 cells caused activa-
tion of endogenous Rac1 and Cdc42, suggesting that in PC12
cells, these two GTPases are targets of downstream signaling
from RhoG (19). We extended these analyses to a different cell
type and also found that activated RhoG caused activation of
endogenous Rac1 and Cdc42 (Fig. 4). To verify the specificity of
these activities, we also evaluated the consequences of acti-
vated GFP-tagged Rac1(61L) and Cdc42(61L). Surprisingly,
these also promoted the apparent activation of endogenous Rac
and Cdc42 (Fig. 4), indicating that the effect seen by exog-
enously expressed activated RhoG in our cells is either a non-
specific artifact of overexpression or possibly reflects a physio-
logical feedback loop in which several Rac/Cdc42-like GTPases
activate each other. In no case did RhoG(61L), Rac1(61L), or
Cdc42(61L) have any effect on the GTP loading of endogenous
RhoA (data not shown), indicating that overexpression of acti-
vated GTPases may only affect the GTP levels of closely related
Rho proteins. Nevertheless, these observations question
whether overexpression of activated mutants of GTPases fol-
lowed by pull-down analysis is a reliable approach to determine
whether one Rho GTPase activates another in a cascade.
RhoG 61L Activates JNK and Akt but Does Not Activate SRF
and NF-B—To further compare the downstream effector in-
teractions of RhoG with those of Rac and Cdc42, we evaluated
the ability of RhoG to activate the JNK mitogen-activated
protein kinase, the Akt serine/threonine kinase, and the SRF
and NF-B nuclear transcription factors. NIH 3T3 cells were
transiently transfected with either empty vector or expression
vector plasmid DNAs encoding RhoG(61L), Rac1(61L), or the
DH-PH domain fragment of the Rac-specific GEF Tiam1 and
then assayed for the activation of the signaling pathways de-
scribed above. We included Tiam1 because RhoG activation of
Rac would likely involve activation of a Dbl-family protein.
Whereas RhoG(61L) activated JNK and Akt to similar levels as
Rac1(61L) (Fig 5, A and B), only Rac1 significantly activated
SRF- or NF-B-dependent gene transcription (Fig. 5, C and D).
Tiam1 DH-PH promoted a weak activation of all four of the
studied pathways. In addition, whereas Rac1(61L) could acti-
vate Pak1, as determined by an activation-specific phospho-
FIG. 2. RhoG binds to effectors of Rac and Cdc42. Expression
vectors encoding epitope-tagged full-length or truncated (containing the
Rho-binding fragments) of Rho family effectors or GAPs were tran-
siently transfected into NIH 3T3 cells. Cell lysates containing the
ectopically expressed proteins were then subjected to pull-down analy-
ses using bacterially expressed GST-tagged constitutively activated
mutants of Cdc42, Rac1, RhoG, or RhoA bound to glutathione Sepha-
rose beads. Binding was detected by SDS-PAGE and immunoblot anal-
yses using monoclonal antibodies to detect the epitope-tagged proteins.
Both wild-type and GTPase-deficient RhoG were used to evaluate the
nucleotide dependence of binding.
FIG. 3. Morphological effects of GFP-tagged activated RhoG
and Rac1 in NIH3T3 cells. NIH 3T3 cells were grown on glass
coverslips and were transfected with expression vectors encoding either
EGFP alone (A and B), or EGFP fusion proteins of RhoG(61L) (C and D),
Rac1(61L) (E and F), Cdc42(61L) (G and H), Rac1(61L) and Cdc42(61L)
(I and J), or oncoVav2 (K and L). After 24 h, the cells were fixed and
stained with Texas Red-labeled phalloidin to visualize filamentous ac-
tin. The coverslips were mounted and analyzed by immunofluorescence
for GFP (A, C, E, G, I, and K) or phalloidin (B, D, F, H, J, and L). Bar 
20 m.
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Pak antibody (46), RhoG(61L) did not (data not shown). These
data indicate, like the effector binding studies, that RhoG ac-
tivates some, but not other, signals that are downstream of
Rac1.
RhoG Morphology Is Not Blocked by Short Term Introduction
of Dominant-Negative Rac1 or the Rac/Cdc42-binding Domain
of Pak1—The morphologic changes caused by activated RhoG
were reported previously to be blocked by co-expression of
either dominant-negative Rac1 or Cdc42 (18). To test this in
our cells, we co-transfected expression vectors for a GFP-tagged
RhoG(61L) mutant and an HA-tagged Rac1(17N) mutant, and
the cells were studied by immunofluorescence analyses after
18 h. Similar to what has been described previously, we also
found that the co-expression of Rac1(17N) inhibited RhoG(61L)-
mediated induction of membrane ruffling and lamellipodia
(data not shown). As a negative control to evaluate the speci-
ficity of these dominant-negative proteins, we tested the effect
of RhoG(17N) when co-expressed with RhoG(61L). Because
Q61L mutants of Rho proteins are activated constitutively in a
GEF-independent manner as a consequence of their impaired
intrinsic and GAP-stimulated GTPase activity, their GTP load-
ing should be insensitive to inhibition by dominant-negative
T17N mutants. Surprisingly, RhoG(17N) also inhibited
RhoG(61L)-induced changes in cell morphology (data not
shown). In addition, we saw that the morphological effects of
Rac1(61L) could be inhibited by co-expression of either
RhoG(17N) or Rac1(17N) (data not shown). To test whether the
effects of the dominant mutants were nonspecifically affecting
the GTP loading of the co-expressed activated mutants, we
performed pull-down analyses for the GTP loading of
Rac1(61L) when expressed alone or when co-expressed with
Rac1(17N) or RhoG(17N). As expected, the dominant-negative
mutants did not lower the GTP loading of Rac1(61L) (data not
shown). Therefore, we concluded that the ability of Rac1(17N)
to block the actions of RhoG(61L) may not reliably demonstrate
that RhoG causes downstream activation of Rac1.
We speculated that the effects of transient overexpression of
this dominant-negative protein may cause nonspecific, and pos-
sibly cytotoxic effects as a consequence of prolonged overex-
pression. Therefore, we utilized short-term approaches to eval-
uate the role of Rac1 activation in RhoG function. For these
analyses, we introduced the dominant-negative Rac1(17N) pro-
tein for shorter periods of time (2–3 h) by either using a mem-
FIG. 4. Activation of endogenous Cdc42 and Rac1 by overex-
pression of activated Rho-family mutants. NIH 3T3 cells were
transiently transfected with the control pEGFP vector alone or with
pEGFP vectors encoding Cdc42(61L), Rac1(61L), or RhoG(61L). Twen-
ty-four h post-transfection, cells were lysed and the amount of active,
GTP-bound Cdc42 and Rac1 was determined by pull-down analyses
using bacterially expressed GST-Pak1 PBD. The relative amounts of
GTP-bound and total (from total cell lysates) Cdc42 and Rac1 was
determined by immunoblot analyses using anti-Cdc42 and anti-Rac1
antibodies. Data shown are representative of four independent
experiments.
FIG. 5. RhoG(61L) activates some,
but not all, Rac/Cdc42-mediated
downstream signaling pathways.
NIH 3T3 cells were transiently trans-
fected with expression plasmids encoding
GFP, GFP-Rac1(61L), GFP-RhoG(61L),
or GFP-Tiam1 DH-PH. Twenty-four h
post-transfection, the cells were lysed and
assayed for JNK (A) and Akt (B) activa-
tion by immunoblot analyses using anti-
bodies that recognize only the phospho-
rylated and activated forms of JNK (A) or
Akt (B). The phospho-specific JNK anti-
body reacted nonspecifically with an ad-
ditional protein migrating slower than
the two isoforms of JNK (both marked
with arrows). Additionally, cells were co-
transfected with reporter plasmids where
the luciferase gene is under the control of
an SRF-responsive (C) or an NF-B-re-
sponsive (D) minimal promoter sequence.
Luciferase activity was determined using
a luminometer as described under “Mate-
rials and Methods.” The luciferase data
presented are the means of triplicate
samples from a representative experi-
ment. The expression levels of the GFP-
tagged proteins were similar in all cases
as determined by immunoblot analyses
for GFP (data not shown).
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brane-permeable tat fusion-tagged Rac1(17N) protein (data not
shown) or by microinjection of a Rac1(17N) expression vector
(data not shown), or alternatively, we introduced GST fusion
protein containing the isolated Rac/Cdc42-binding fragment of
Pak1 (Pak1-PBD) to block Rac and Cdc42-dependent down-
stream signaling (Fig. 6). When dominant-negative Rac1 was
introduced for a short period of time, we did not see loss of
either Rac1(61L)- or RhoG(61L)-mediated induction of morpho-
logical effects (data not shown). In contrast, the induction of
membrane ruffling and lamellipodia caused by expression of
GFP-tagged DH-PH fragment of Tiam1 was effectively blocked,
indicating that the dominant-negative protein was functional
under these assay conditions (data not shown). When we intro-
duced GST-Pak1 PBD, we potently inhibited the morphological
effects of both Rac(61L) (Fig. 6, A, B, and G) and constitutively
activated Tiam1(C1199) activation of endogenous Rac (Fig. 6,
E, F, and G). The RhoG-dependent morphological effects, on
the other hand, were largely unaffected by the addition of the
Rac/Cdc42-inhibitory fragment (Fig. 6, C, D, and G). These
results argue that under our assay conditions, the morpholog-
ical effects induced by activated RhoG are not dependent on a
downstream activation of Rac1.
DISCUSSION
RhoG shares strongest sequence similarity with Rac and
Cdc42. Therefore, it is not surprising that RhoG exhibits func-
tions similar to those regulated by Rac and Cdc42. However,
previous studies suggested that this overlap in function is not
a consequence of RhoG utilization of downstream effector tar-
gets shared with Rac and Cdc42. Instead, a model has been
described whereby RhoG regulates changes in actin organiza-
tion and stimulates signal transduction by causing down-
stream activation of Rac and Cdc42 (18). In the present study,
we have evaluated the ability of upstream and downstream
regulators of Rac and Cdc42 to regulate RhoG function. First,
we determined that some Dbl-family proteins that activate
RhoA, Rac1, and Cdc42 also activate RhoG, indicating that
RhoG can be activated concurrently with other Rho GTPases.
Second, we found that RhoG can interact with some, but not all,
effectors of Rac and/or Cdc42. Finally, we determined that
dominant-negative Rac1 or the Rac/Cdc42-binding fragment of
Pak1 failed to block RhoG signaling under conditions in which
Rac activation by Tiam1 was blocked effectively. Taken to-
gether, these observations argue that RhoG may also mediate
functions shared with Rac and Cdc42 by utilization of common
effectors. To date, no extracellular stimuli have been described
that cause activation of RhoG via stimulation of GTP binding.
Instead, RhoG mRNA expression was shown to be stimulated
by serum and peptide growth factors (47). Previous studies had
determined that Dbl-family proteins that can cause activation
of Rac (e.g. Vav and Trio) also cause activation of RhoG. We
extended these observations and found that some (Vav2), but
not all (Tiam1), Rac GEFs can activate RhoG. Additionally, we
found that the Cdc42 and/or RhoA GEFs, Dbl, Dbs, and Ect,
bind to RhoG in vitro and could therefore possibly function as
RhoG exchange factors in vivo. In summary, we have extended
the repertoire of Dbl family proteins that can cause activation
of RhoG, providing further evidence for RhoG activation by
diverse extracellular stimuli.
Consistent with the ability of RhoG to signal in parallel with
Cdc42 and Rac1, we found that RhoG showed GTP-dependent
binding to some Cdc42/Rac1 effectors (IQGAP2, MLK3, and
PLD1). It could therefore be expected for RhoG to signal by
direct association with these proteins and trigger their down-
stream signals. For example, MLK3 mediates Rac1 activation
of JNK as well as p70 S6 kinase (33, 48). Hence, RhoG is likely
to activate these kinase cascades directly, rather than via in-
direct activation of Rac or Cdc42. On the other hand, RhoG did
not bind to a number of other Rac1/Cdc42 effectors that were
tested (Pak1, Pak5, Pak6, WASP, Par6, POSH, and IRSp53).
IRSp53, which was originally described to link Rac1 to WAVE/
Arp2/3 and lamellipodia formation (49), only bound Cdc42, in
agreement with two recent reports (50, 51). Our observation
that RhoG can activate some Cdc42/Rac1 downstream path-
ways, but not others, provides further evidence that RhoG does
not mediate its cellular effects solely through activation of
Cdc42 and Rac1. If this had been the case, one would have
expected that RhoG would cause activation of the same signal-
ing pathways activated by Cdc42/Rac1. For example, RhoA,
Rac1, and Cdc42 have all been shown to activate NF-B and
SRF (52, 53), yet we found that RhoG failed to activate these
transcription factors.
One key observation that supported a model in which RhoG
mediates its functions by downstream activation of Rac and
Cdc42 was that activated RhoG causes increases in the levels of
GTP-bound Rac1 and Cdc42. In agreement with these previous
studies (19), we also found that transient overexpression of
activated RhoG caused increased GTP loading of endogenous
Cdc42 and Rac1. However, we also unexpectedly detected a
FIG. 6. Tiam1- and Rac1(61L) but not RhoG(61L)-dependent
morphology is inhibited by transient transduction of the Rac/
Cdc42 binding fragment of Pak1. NIH 3T3 cells were grown on
coverslips and were then transfected with expression vectors encoding
GFP-tagged Rac1(61L), RhoG(61L), or Myc epitope-tagged
Tiam1(C1199). After 24 h, the growth medium was replaced with se-
rum-free medium. Five g of either GST (A, C, and E) or GST-Pak1
PBD (B, D, and F) mixed with LipofectAMINE was added to each well.
After 2 h, the cells were fixed, stained, and analyzed by immunofluo-
rescence for expression of the GFP- or Myc-tagged proteins (green) and
the presence of filamentous actin (red). Bar  20 m. Approximately
200 cells from each condition were scored for expression of a lamellipo-
dial phenotype, and the percentages of cells with this phenotype were
calculated (G).
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similar activation of endogenous Cdc42 and Rac1 by overex-
pressing activated Rac1 or Cdc42. One possible explanation for
the apparent increase of GTP-loaded endogenous Rac1 and
Cdc42 could be due to the possibility that the overexpressed
activated mutants have sequestered GAPs that would normally
inactivate the endogenous proteins. An alternative explanation
could be that activation of phosphatidylinositol 3-kinase down-
stream of all three GTPases leads to an activating feedback
loop by activating GEFs (54, 55). Either way, these results
argue that the ability of RhoG to activate Rac and Cdc42 may
not simply reflect the most straightforward interpretation, that
RhoG specifically causes downstream activation of Rac and
Cdc42. Thus, whether activation of endogenous RhoG can in
turn activate Rac and Cdc42 remains unanswered from these
studies using constitutively activated and overexpressed Rho
GTPases. Clearly, caution must be exercised when using these
mutants to define the downstream signaling pathways nor-
mally stimulated by the endogenously activated protein.
A second key observation that implicated Rac and Cdc42
activation downstream of RhoG was the demonstrated ability
of dominant-negative Rac1 and Cdc42 to block the ability of
RhoG to cause actin reorganization. Consistent with these pre-
vious studies (18, 19), we also saw that co-expression of domi-
nant-negative Rac1 inhibited the morphology caused by acti-
vated RhoG. However, we found that dominant-negative Rac1
blocked the activity of activated Rac1(61L) as well. Because
this mutant is activated by a defect in GAP responsiveness and
is activated independent of GEF activity, the inhibition caused
by Rac1(17N) may be an artifact of overexpression and hence
prevent a straightforward interpretation of Rac1 function
downstream of RhoG. Although dominant-negative Rho GTP-
ases have been utilized extensively and have shown remarka-
ble specificity of action in many studies, our results here em-
phasize the potential nonspecific actions of these mutants
when expressed at high levels for prolonged time periods. In-
stead, when we expressed the same dominant-negative of Rac1
for a short period of time and under conditions in which the
level of expression can be better controlled, we did not see an
effect of Rac1(17N) on the morphology induced by activated
forms of RhoG or Rac1, even though it efficiently inhibited the
morphology caused by a DH-PH fragment of Tiam1, a Rac-
specific GEF. Furthermore, when we did short time period
transduction of the Rac/Cdc42-binding fragment of Pak1,
which binds to GTP-bound Rac1 and Cdc42, but not RhoG, we
observed strong inhibition of lamellipodia formation caused by
activated Rac1 and activated Tiam1. RhoG-dependent lamelli-
podia formation, on the other hand, was unaffected by the
addition of this fragment, strongly arguing that the morpho-
logical effects caused by activated mutants of RhoG are not
mediated by activation of Rac1.
In summary, we conclude that RhoG mediates functions
independent of causing activation of Rac and Cdc42. Although
it certainly remains possible that such a GTPase cascade may
still mediate some functions of RhoG, our findings indicate that
overexpression of constitutively activated or dominant-nega-
tive Rho GTPases may cause artifactual signaling events that
do not accurately reflect the signaling functions of endog-
enously activated Rho GTPases. Together, our data along with
the previous observations that RhoG cooperates with Rac1 and
Cdc42 in cellular transformation (17) emphasize that RhoG
function can be mediated by its direct interaction with effec-
tors. This raises the question of what effectors for RhoG exist in
the cell. In addition to the three potential RhoG effectors that
we have described here, IQGAP2, MLK3, and PLD1, two addi-
tional effectors have been described. The first one is the frag-
ment RhoGIP122 (22). The full-length protein from which this
fragment is derived has not yet been characterized, so the
function of this potential effector is still unknown. More re-
cently, kinectin was identified as a RhoG effector. Kinectin
binds RhoG in a GTP-dependent manner (56), possibly coupling
RhoG to kinesin and the microtubule cytoskeleton, an observa-
tion that is consistent with earlier reports that RhoG localizes
to microtubules (18). As suggested by Vignal and coworkers,
this could also contribute to the polarized phenotype of cells
expressing activated RhoG. Future studies in our laboratories
will be aimed at defining the individual roles of the known
RhoG effectors as well as searching for new, additional RhoG-
specific effectors.
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